{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ellipta",
    "query": {
      "intervention": "Ellipta"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ellipta&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T09:11:47.886Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07133880",
      "title": "Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD (Chronic Obstructive Pulmonary Disease)"
      ],
      "interventions": [
        {
          "name": "umeclidinium 62.5 µg and vilanterol 25 µg",
          "type": "DRUG"
        },
        {
          "name": "Revefenacin 175 µg, Formoterol 20 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo ( Revefenacin and Formoterol )",
          "type": "DRUG"
        },
        {
          "name": "Placebo DPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-12-05",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07133880"
    },
    {
      "nct_id": "NCT02799784",
      "title": "An Efficacy Study of Umeclidinium/Vilanterol With Tiotropium/Olodaterol in COPD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI",
          "type": "DRUG"
        },
        {
          "name": "TIO/OLO",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 236,
      "start_date": "2016-07-14",
      "completion_date": "2017-04-27",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 9,
      "location_summary": "Clearwater, Florida • Orlando, Florida • St Louis, Missouri + 6 more",
      "locations": [
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Medford",
          "state": "Oregon"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02799784"
    },
    {
      "nct_id": "NCT02924688",
      "title": "A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "FF/UMEC/VI (100/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (100/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/31.25/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/UMEC/VI (200/62.5/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (100/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "FF/VI (200/25) mcg",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone/salmeterol (FSC)",
          "type": "DRUG"
        },
        {
          "name": "Albuterol/salbutamol",
          "type": "DRUG"
        },
        {
          "name": "ELLIPTA DPI",
          "type": "DEVICE"
        },
        {
          "name": "DISKUS DPI",
          "type": "DEVICE"
        },
        {
          "name": "METERED-DOSE INHALER (MDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2436,
      "start_date": "2016-10-13",
      "completion_date": "2019-02-22",
      "has_results": true,
      "last_update_posted_date": "2021-03-26",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 99,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02924688"
    },
    {
      "nct_id": "NCT03002389",
      "title": "Hyperpolarized Xenon-129 MRI: a New Multi-dimensional Biomarker to Determine Pulmonary Physiologic Responses to COPD Therapeutics",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Obstructive Pulmonary Disease"
      ],
      "interventions": [
        {
          "name": "Anoro Ellipta",
          "type": "DRUG"
        },
        {
          "name": "Arnuity Ellipta",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Virginia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 95,
      "start_date": "2017-11-05",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2024-11-18",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 1,
      "location_summary": "Keswick, Virginia",
      "locations": [
        {
          "city": "Keswick",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03002389"
    },
    {
      "nct_id": "NCT03543176",
      "title": "Chronic Obstructive Pulmonary Disease (COPD) Dual Therapy Burden of Illness",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "UMEC/VI",
          "type": "OTHER"
        },
        {
          "name": "FLUT/SAL",
          "type": "OTHER"
        },
        {
          "name": "CAT",
          "type": "OTHER"
        },
        {
          "name": "mMRC",
          "type": "OTHER"
        },
        {
          "name": "Ellipta",
          "type": "DEVICE"
        },
        {
          "name": "Diskus",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 789,
      "start_date": "2018-05-31",
      "completion_date": "2019-08-21",
      "has_results": true,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03543176"
    },
    {
      "nct_id": "NCT02135718",
      "title": "ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "ELLIPTA inhaler",
          "type": "DEVICE"
        },
        {
          "name": "Placebo Inhalation Aerosol (MDI)",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 288,
      "start_date": "2014-06",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2016-06-08",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 15,
      "location_summary": "Huntington Beach, California • Newport Beach, California • Vista, California + 12 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Vista",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02135718"
    },
    {
      "nct_id": "NCT02301975",
      "title": "An Efficacy and Safety Study of Fluticasone Furoate/Vilanterol 100/25 Microgram (mcg) Inhalation Powder, Fluticasone Propionate/Salmeterol 250/50 mcg Inhalation Powder, and Fluticasone Propionate 250 mcg Inhalation Powder in Adults and Adolescents With Persistent Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powders via ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Placebo inhalation powder via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 1526,
      "start_date": "2015-03-01",
      "completion_date": "2016-11-25",
      "has_results": true,
      "last_update_posted_date": "2018-08-06",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 34,
      "location_summary": "Huntington Beach, California • Riverside, California • Rolling Hills Estates, California + 30 more",
      "locations": [
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Rolling Hills Estates",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Upland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02301975"
    },
    {
      "nct_id": "NCT02586506",
      "title": "Study of the Ease of Use and Correct Use of Placebo ELLIPTA® Inhaler in Subjects With Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo ELLIPTA inhaler",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 259,
      "start_date": "2015-10-01",
      "completion_date": "2016-02-04",
      "has_results": true,
      "last_update_posted_date": "2017-10-11",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 15,
      "location_summary": "Mobile, Alabama • Huntington Beach, California • Aventura, Florida + 12 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        },
        {
          "city": "Aventura",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Sunset",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02586506"
    },
    {
      "nct_id": "NCT02586493",
      "title": "Ease of Use and Correct Use Study of Placebo ELLIPTA® Inhaler in COPD Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 278,
      "start_date": "2015-10-01",
      "completion_date": "2016-03-15",
      "has_results": true,
      "last_update_posted_date": "2017-11-09",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 16,
      "location_summary": "Jasper, Alabama • Clearwater, Florida • Orlando, Florida + 13 more",
      "locations": [
        {
          "city": "Jasper",
          "state": "Alabama"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Ormond Beach",
          "state": "Florida"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02586493"
    },
    {
      "nct_id": "NCT03949842",
      "title": "Legend: TRELEGY Real World Chronic Obstructive Pulmonary Disease (COPD) Effectiveness Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Inhaled corticosteroids/long-acting beta2-adrenergic/long-acting muscarinic receptor antagonists",
          "type": "DRUG"
        },
        {
          "name": "Fluticasone furoate/umeclidinium/vilanterol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-06-27",
      "completion_date": "2022-11-30",
      "has_results": false,
      "last_update_posted_date": "2020-04-22",
      "last_synced_at": "2026-09-03T09:11:47.886Z",
      "location_count": 3,
      "location_summary": "Waterbury, Connecticut • Charlotte, North Carolina • Layton, Utah",
      "locations": [
        {
          "city": "Waterbury",
          "state": "Connecticut"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Layton",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03949842"
    }
  ]
}